First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial

Authors: Pasi A. Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W. Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Florin Vranceanu, Annette Szumski, Huamao M. Lin, Robert J. Fram, Tony S.K. Mok

Source: J Clin Oncol
Journal of clinical oncology, vol. 43, no. 13, pp. 1553-1563

Subject Terms: Male, Adult, Aged, 80 and over, Lung Neoplasms, Aniline Compounds, Indoles, ORIGINAL REPORTS, Pemetrexed, Exons, Middle Aged, Progression-Free Survival, Carboplatin, ErbB Receptors, Pyrimidines, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, Carboplatin/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/enzymology, Cisplatin/administration & dosage, Cisplatin/adverse effects, ErbB Receptors/genetics, ErbB Receptors/antagonists & inhibitors, Lung Neoplasms/drug therapy, Lung Neoplasms/genetics, Lung Neoplasms/pathology, Lung Neoplasms/enzymology, Pemetrexed/administration & dosage, Pemetrexed/adverse effects, Protein Kinase Inhibitors/therapeutic use, Protein Kinase Inhibitors/adverse effects, Cisplatin, Protein Kinase Inhibitors

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39879577
https://serval.unil.ch/notice/serval:BIB_F1541B0B9B82
https://serval.unil.ch/resource/serval:BIB_F1541B0B9B82.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_F1541B0B9B821

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors: Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors

Authors: Jia Liu, Anna R. Minchom, Alastair Greystoke, Thomas R.J. Evans, Debashis Sarker, Anthony M. Joshua, Cienne Morton, Wing Yau, Burak Y. Aktas, Rasha Cosman, Jordan E. Cohen, Stephanie R. Edmondson, Jeremy R.A. Paull, Bernadette M. Jean-Francois, Nicola J. Main, Julia Angeles, Alex Castellarnau, Natalie Cook

Source: Liu, J, Minchom, A R, Greystoke, A, Evans, T R J, Sarker, D, Joshua, A M, Morton, C, Yau, W, Aktas, B Y, Cosman, R, Cohen, J E, Edmondson, S R, Paull, J R A, Jean-Francois, B M, Main, N J, Angeles, J, Castellarnau, A & Cook, N 2025, 'Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38) : Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 43, no. 26, pp. 2918-2929. https://doi.org/10.1200/JCO-25-00236

Subject Terms: Aged, 80 and over, Adult, Male, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Australia, Middle Aged, Dendrimers/administration & dosage, United Kingdom, Neoplasms/drug therapy, Young Adult, Fluorouracil/administration & dosage, 80 and over, Leucovorin/administration & dosage, Humans, Camptothecin/analogs & derivatives, Nanoparticles, Female, Irinotecan/administration & dosage, Topoisomerase I Inhibitors/administration & dosage, Aged

Access URL: https://research.manchester.ac.uk/en/publications/cf87f32e-504b-4ac4-942d-945c3d716e87
https://doi.org/10.1200/JCO-25-00236

Health‐Related Quality of Life During Carfilzomib–Lenalidomide–Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study: Findings From the Multiple Myeloma CONPET Study

Authors: Tine Rosenberg, Sören Möller, Niels Abildgaard, Jakob Nordberg Nørgaard, Anna Lysén, Galina Tsykonova, Cristina Joao, Annette Vangsted, Fredrik Schjesvold, Lene Kongsgaard Nielsen

Source: Rosenberg, T, Möller, S, Abildgaard, N, Nørgaard, J N, Lysén, A, Tsykonova, G, Joao, C, Vangsted, A, Schjesvold, F & Nielsen, L K 2025, 'Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation : Findings From the Multiple Myeloma CONPET Study', European Journal of Haematology, vol. 114, no. 3, pp. 517-527. https://doi.org/10.1111/ejh.14358

Subject Terms: Dexamethasone/administration & dosage, Male, carfilzomib, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Multiple Myeloma/drug therapy, clinical trial, Dyspnea/diagnosis, Middle Aged, multiple myeloma, Oligopeptides/administration & dosage, side effects, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, quality of life, patient-reported outcomes, Quality of Life, Humans, Lenalidomide/administration & dosage, Female, Aged

Access URL: https://pubmed.ncbi.nlm.nih.gov/39638553
https://portal.findresearcher.sdu.dk/da/publications/9173256f-6496-479b-b8dd-2857e0c55df7
https://doi.org/10.1111/ejh.14358
http://www.scopus.com/inward/record.url?scp=85210995772&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/063b7cfa-94c8-4baa-9057-800342db8809
https://doi.org/10.1111/ejh.14358

Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients

Authors: Badawi, Mohamed Ali, Engelhardt, Benjamin, Dobkowska, Edyta, Deng, Rong, Kaufman, Jonathan L., Menon, Rajeev, Salem, Ahmed Hamed

Source: Invest New Drugs

Subject Terms: Male, Adult, Aged, 80 and over, Chromosomes, Human, Pair 14, Sulfonamides, Research, Chromosomes, Human, Pair 11, Multiple myeloma, Aged, 80 and over [MeSH], Aged [MeSH], Bridged Bicyclo Compounds, Heterocyclic/administration, Carfilzomib, Dexamethasone/adverse effects [MeSH], Multiple Myeloma/genetics [MeSH], Sulfonamides/adverse effects [MeSH], Sulfonamides/therapeutic use [MeSH], Male [MeSH], Bridged Bicyclo Compounds, Heterocyclic/therapeutic use [MeSH], Oligopeptides/adverse effects [MeSH], Dexamethasone/administration, Venetoclax, Oligopeptides/therapeutic use [MeSH], Multiple Myeloma/drug therapy [MeSH], Bridged Bicyclo Compounds, Heterocyclic/adverse effects [MeSH], Dexamethasone/therapeutic use [MeSH], Female [MeSH], Adult [MeSH], Translocation, Genetic [MeSH], Dose selection, Humans [MeSH], Chromosomes, Human, Pair 11 [MeSH], Exposure-response, Middle Aged [MeSH], Chromosomes, Human, Pair 14 [MeSH], Sulfonamides/administration, Antineoplastic Combined Chemotherapy Protocols/administration, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Oligopeptides/administration, Relapsed/refractory, Middle Aged, Bridged Bicyclo Compounds, Heterocyclic, Dexamethasone, Translocation, Genetic, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Multiple Myeloma, Oligopeptides, Aged

Access URL: https://pubmed.ncbi.nlm.nih.gov/39388024
https://repository.publisso.de/resource/frl:6496067

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

Authors: Van Cutsem, Eric, Collignon, Joëlle, Eefsen, Rikke L, Ochsenreither, Sebastian, Zvirbule, Zanete, Ivanauskas, Audrius, Arnold, Dirk, Baltruskeviciene, Edita, Pfeiffer, Per, Yachnin, Jeffrey, Magnusson, Susanne, Rydberg Millrud, Camilla, Sanfridson, Annika, Losic, Nedjad, Garcia-Ribas, Ignacio, Tersago, Dominique, Awada, Ahmad

Source: Clin Cancer Res

Subject Terms: Male, Pancreatic Neoplasms/pathology, Oncologie, Carcinoma, Pancreatic Ductal/drug therapy, Deoxycytidine, ACTIVATION, Deoxycytidine/analogs & derivatives, Pancreatic Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel/adverse effects, Human health sciences, Neoplasm Metastasis, Aged, 80 and over, CHEMORESISTANCE, Carcinoma, Pancreatic Ductal/immunology, Medicine (all), Middle Aged, Treatment Outcome, Oncology, Antibodies, Monoclonal, Humanized/adverse effects, Female, Pancreatic Neoplasms/immunology, Life Sciences & Biomedicine, Albumins/administration & dosage, Antibodies, Monoclonal, Humanized/administration & dosage, Carcinoma, Pancreatic Ductal, Adult, Paclitaxel, Clinical Trials: Targeted Therapy, Carcinoma, Pancreatic Ductal/pathology, Antibodies, Monoclonal, Humanized, Sciences de la santé humaine, POOR-PROGNOSIS, Paclitaxel/administration & dosage, 3211 Oncology and carcinogenesis, Albumins, Biomarkers, Tumor, Pancreatic Neoplasms/mortality, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Deoxycytidine/administration & dosage, Aged, Albumins/adverse effects, Science & Technology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, IL1RAP protein, human, 3202 Clinical sciences, 130-nm albumin-bound paclitaxel, Gemcitabine, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Interleukin-1 Receptor Accessory Protein, Deoxycytidine/therapeutic use

Access URL: https://pubmed.ncbi.nlm.nih.gov/39385434
https://lirias.kuleuven.be/handle/20.500.12942/769085
https://doi.org/10.1158/1078-0432.ccr-24-0645
https://hdl.handle.net/2268/333840
https://doi.org/10.1158/1078-0432.CCR-24-0645

An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma

Authors: Christofyllakis, Konstantinos, Kaddu-Mulindwa, Dominic, Lesan, Vadim, Rixecker, Torben, Kos, Igor Age, Held, Gerhard, Regitz, Evi, Pfreundschuh, Michael, Bittenbring, Joerg Thomas, Thurner, Lorenz, Poeschel, Viola, Ziepert, Marita, Altmann, Bettina, Bewarder, Moritz

Source: Ann Hematol

Subject Terms: Adult, Male, Lymphoma, B-Cell, Genotype, Adolescent, Cell Cycle Proteins, Polymorphism, Single Nucleotide, Young Adult, Polyneuropathy, Antineoplastic Combined Chemotherapy Protocols, Humans, Genetic Predisposition to Disease, Cyclophosphamide, Aged, Aged, 80 and over, ddc:610, Research, Peripheral Nervous System Diseases, Middle Aged, Single nucleotide polymorphism, Vincristine, Aggressive lymphoma, DLBCL, Prednisone, Female, Pharmacogenomics, FOS: Medical biotechnology, Cell Cycle Proteins/genetics [MeSH], Aged, 80 and over [MeSH], Lymphoma, B-Cell/drug therapy [MeSH], Aged [MeSH], Polymorphism, Single Nucleotide [MeSH], Prednisone/adverse effects [MeSH], Cyclophosphamide/therapeutic use [MeSH], Cyclophosphamide/adverse effects [MeSH], Lymphoma, B-Cell/genetics [MeSH], Cyclophosphamide/administration, Male [MeSH], Prednisone/therapeutic use [MeSH], Peripheral Nervous System Diseases/chemically induced [MeSH], Genetic Predisposition to Disease [MeSH], Adolescent [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Middle Aged [MeSH], Peripheral Nervous System Diseases/genetics [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Prednisone/administration, Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Young Adult [MeSH], Genotype [MeSH], Vincristine/adverse effects [MeSH], Microtubule-Associated Proteins/genetics [MeSH], Microtubule-Associated Proteins

Access URL: https://pubmed.ncbi.nlm.nih.gov/39227453
https://repository.publisso.de/resource/frl:6523196

Intestinal mucositis, systemic inflammation and bloodstream infections following high‐dose methotrexate treatment in childhood acute lymphoblastic leukaemia: Comparison between the NOPHO ALL 2008 protocol and the ALLTogether1 protocol: Comparison between the NOPHO ALL 2008 protocol and the ALLTogether1 protocol

Authors: Sarah Weischendorff, Silvia de Pietri, Mathias Rathe, Kjeld Schmiegelow, Thomas Leth Frandsen, Malene Johanne Petersen, Allan Weimann, Claus Henrik Nielsen, Christian Enevold, Helin Berna Kocadag, Claus Moser, Klaus Müller

Source: Weischendorff, S, de Pietri, S, Rathe, M, Schmiegelow, K, Frandsen, T L, Petersen, M J, Weimann, A, Nielsen, C H, Enevold, C, Kocadag, H B, Moser, C & Müller, K 2025, ' Intestinal mucositis, systemic inflammation and bloodstream infections following high-dose methotrexate treatment in childhood acute lymphoblastic leukaemia : Comparison between the NOPHO ALL 2008 protocol and the ALLTogether1 protocol ', International Journal of Cancer, vol. 156, no. 1, pp. 164-173 . https://doi.org/10.1002/ijc.35136

Subject Terms: Mucositis, Male, Methotrexate/adverse effects, acute lymphoblastic leukaemia, bloodstream infections, Adolescent, C-Reactive Protein/analysis, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Preschool, high-dose methotrexate, Child, systemic inflammation, Inflammation, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, intestinal mucositis, Methotrexate, C-Reactive Protein, Mucositis/chemically induced, Child, Preschool, Citrulline, Female, CCL20

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39150399
https://curis.ku.dk/ws/files/411638560/Intl_Journal_of_Cancer_2024_Weischendorff_Intestinal_mucositis_systemic_inflammation_and_bloodstream_infections.pdf
https://portal.findresearcher.sdu.dk/da/publications/52fddf8c-d97c-4edb-ad3f-bc181f6eb848
https://doi.org/10.1002/ijc.35136

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Authors: Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., Lee, Jung-Yun, Banerjee, Susana, Maluf, F.C., Lorusso, D., Yonemori, K., Nieuwenhuysen, E. Van, Manso, L., Woelber, L., Westermann, A., Covens, A., Hasegawa, K., Kim, B.G., Raimondo, M., Bjurberg, M., Cruz, F.M., Angelergues, A., Cibula, D., Barraclough, L., Oaknin, A., Gennigens, C., Nicacio, L., Teng, M.S.L., Whalley, E., Ottevanger, P.B., Soumaoro, I., Slomovitz, B.M.

Contributors: Genmab, Pfizer

Source: The New England Journal of Medicine, 391, 1, pp. 44-55

Subject Terms: Adult, Oncologie, Uterine Cervical Neoplasms, Antibodies, Monoclonal/therapeutic use, Kaplan-Meier Estimate, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/administration & dosage, Sciences de la santé humaine, Uterine Cervical Neoplasms/mortality, Antineoplastic Combined Chemotherapy Protocols, Humans, Uterine Cervical Neoplasms/drug therapy, Human health sciences, Medical Oncology - Radboud University Medical Center, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antibodies, Monoclonal, Middle Aged, Survival Analysis, Progression-Free Survival, Neoplasm Recurrence, Local/drug therapy, Oncology, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Recurrence, Local, Oligopeptides

Access URL: https://pubmed.ncbi.nlm.nih.gov/38959480
https://hdl.handle.net/2066/310949
https://repository.ubn.ru.nl//bitstream/handle/2066/310949/310949.pdf

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Authors: Alexander D Murphy, Catharine Porter, Ann White, Alys Irving, Richard Adams, Ruby Ray, Angela Casbard, Reem D Mahmood, Suman Karanth, Cong Zhou, Julia Pugh, Chelsey Wheeler, Victoria Roberts, Giorgio Arnetoli, Zena Salih, Jurjees Hasan, Claire Mitchell, Robert D Morgan, Andrew R Clamp, Gordon C Jayson

Source: AD, M, Porter, C, White, A, Irving, A, Adams, R, Ray, R, Casbard, A, Mahmood, R, Karanth, S, Zhou, C, Pugh, J, Wheeler, C, Roberts, V, Arnetoli, G, Salih, Z, Hasan, J, Mitchell, C, Morgan, R, Clamp, A & Jayson, G 2024, 'Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol. 34, no. 7, pp. 1034-1040. https://doi.org/10.1136/ijgc-2024-005455

Subject Terms: Adult, Indoles, Paclitaxel, Drug Resistance, Carcinoma, Ovarian Epithelial, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Paclitaxel/administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Humans, Carcinoma, Ovarian Epithelial/drug therapy, Aged, Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carcinoma, Ovarian Neoplasms/drug therapy, Middle Aged, Quinazolines/administration & dosage, 3. Good health, Ovarian Epithelial/drug therapy, Drug Resistance, Neoplasm, Intestinal Obstruction/chemically induced, Quinazolines, Neoplasm, Female, Intestinal Obstruction

Access URL: https://pubmed.ncbi.nlm.nih.gov/38724236
https://research.manchester.ac.uk/en/publications/ce1b52c5-2554-4e13-926c-ba7fd010053c
https://doi.org/10.1136/ijgc-2024-005455
https://research.manchester.ac.uk/en/publications/ce1b52c5-2554-4e13-926c-ba7fd010053c
https://orca.cardiff.ac.uk/id/eprint/169252/1/ijgc-2024-005455.pdf
https://doi.org/10.1136/ijgc-2024-005455

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial: the Nordic Lymphoma Group MCL7 VALERIA trial

Authors: Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius

Contributors: HUS Comprehensive Cancer Center, Department of Oncology

Source: Blood Adv
Jerkeman, M, Kolstad, A, Hutchings, M, Pasanen, A, Meriranta, L, Niemann, C U, Kragh Jørgensen, R R, El-Galaly, T C, Riise, J, Leppä, S, Christensen, J H, Sonnevi, K, Pedersen, L B, Wader, K F & Glimelius, I 2024, 'MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial', Blood advances, vol. 8, no. 2, pp. 407-415. https://doi.org/10.1182/bloodadvances.2023011920

Subject Terms: Adult, Sulfonamides, Neoplasm, Residual, Clinical Trials and Observations, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Neoplasm, Residual/drug therapy, Lymphoma, Mantle-Cell, Bridged Bicyclo Compounds, Heterocyclic, 3. Good health, Lenalidomide/therapeutic use, Neoplasm Recurrence, Local/drug therapy, Rituximab/adverse effects, Rituximab/therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Recurrence, Local, Cancers, Rituximab, Lenalidomide, Aged

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38113470
https://vbn.aau.dk/da/publications/e1016e94-29e3-4637-ba18-dd36853a40fa
https://vbn.aau.dk/ws/files/638275389/Jerkeman_et_al._2024_._MRD-driven_treatment_with_venetoclax-R2_in_mantle_cell_lymphoma_-_the_Nordic_Lymphoma_Group_MCL7_VALERIA_trial.pdf
https://doi.org/10.1182/bloodadvances.2023011920
http://hdl.handle.net/10138/593253
https://portal.findresearcher.sdu.dk/da/publications/b7c4d81d-0351-4fb2-89af-87e9a5468026
https://doi.org/10.1182/bloodadvances.2023011920

The Current State of Systemic Therapy of Metastatic Uveal Melanoma

Authors: Elias A. T. Koch, Markus V. Heppt, Carola Berking

Source: Am J Clin Dermatol

Subject Terms: Uveal Neoplasms, Humans [MeSH], Melanoma/secondary [MeSH], Uveal Neoplasms/drug therapy [MeSH], Skin Neoplasms/drug therapy [MeSH], Skin Neoplasms/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Molecular Targeted Therapy [MeSH], Randomized Controlled Trials as Topic [MeSH], Liver Neoplasms/secondary [MeSH], Melanoma/pathology [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Uveal Neoplasms/pathology [MeSH], Melanoma/drug therapy [MeSH], Liver Neoplasms/drug therapy [MeSH], Leading Article, Skin Neoplasms, Uveal Melanoma, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Antineoplastic Agents, Molecular Targeted Therapy, Melanoma, Immune Checkpoint Inhibitors, Randomized Controlled Trials as Topic

Access URL: https://pubmed.ncbi.nlm.nih.gov/38907174
https://repository.publisso.de/resource/frl:6499367

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Authors: Chalandon, Yves, Rousselot, Philippe, Chevret, Sylvie, Cayuela, Jean-Michel, Kim, Rathana, Huguet, Françoise, Chevallier, Patrice, Graux, Carlos, Thiebaut-Bertrand, Anne, Chantepie, Sylvain, Thomas, Xavier, Vincent, Laure, Berthon, Céline, Hicheri, Yosr, Raffoux, Emmanuel, Escoffre-Barbe, Martine, Plantier, Isabelle, Joris, Magalie, Turlure, Pascal, Pasquier, Florence, Belhabri, Amine, Guepin, Gabrielle Roth, Blum, Sabine, Gregor, Michael, Lafage-Pochitaloff, Marina, Quessada, Julie, Lhéritier, Véronique, Clappier, Emmanuelle, Boissel, Nicolas, Dombret, Hervé

Contributors: UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie

Source: Blood, Vol. 143, no.23, p. 2363-2372 (2024)

Subject Terms: Male, Adult, Adolescent, Cytarabine / therapeutic use, Fusion Proteins, bcr-abl / genetics, Fusion Proteins, bcr-abl, Young Adult, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Pyrimidines / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy, Cytarabine, Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrimidines / administration & dosage, 3. Good health, Cytarabine / administration & dosage, Pyrimidines, Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy, Female, Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38452207
https://hdl.handle.net/2078.1/289800

Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial

Authors: Guigay, Joël, Le Caer, Hervé, Ferrand, François-Régis, Geoffrois, Lionel, Saada-Bouzid, Esma, Fayette, Jérôme, Sire, Christian, Cupissol, Didier, Blot, Emmanuel, Guillet, Pierre, Pavillet, Julien, Bozec, Laurence, Capitain, Olivier, Rolland, Frédéric, Debourdeau, Philippe, Pointreau, Yoann, Falandry, Claire, Lopez, Stéphane, Coutte, Alexandre, Chatellier, Thierry, Dalloz, Pierre, Ortholan, Cécile, Michel, Cécile, Lacas, Benjamin, Cheurfa, Nadir, Schwob, Dominique, Bourhis, Jean, Mertens, Cécile, Aupérin, Anne

Contributors: Catois, Jacques-Olivier, ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups, and GORTEC, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital de Saint-Brieuc Hôpital Yves Le Foll, Centre hospitalier Saint-Brieuc Paimpol Tréguier (CH Saint-Brieuc Paimpol Tréguier), Groupement Hospitalier Territoire d'Armor (GHT Armor)-Groupement Hospitalier Territoire d'Armor (GHT Armor), Institut Gustave Roussy (IGR), Institut de Cancérologie de Lorraine - Alexis Vautrin Nancy (UNICANCER/ICL), UNICANCER, Centre de Lutte contre le Cancer Antoine Lacassagne Nice (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UniCA), Université Côte d'Azur (UniCA), Centre Léon Bérard Lyon, Groupe Hospitalier Bretagne Sud (GHBS), Institut régional de Cancérologie de Montpellier (ICM), Clinique chirurgicale Porte Océane, Centre Hospitalier Intercommunal de Toulon La Seyne-sur-Mer, Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Institut Curie - Saint Cloud (ICSC), Institut de Cancérologie de l'Ouest Angers/Nantes (UNICANCER/ICO), Institut Sainte Catherine Avignon, Centre Jean Bernard Institut Inter-régional de Cancérologie - Le Mans, Clinique Victor Hugo Le Mans, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Annecy-Genevois Saint-Julien-en-Genevois, CHU Amiens-Picardie, Clinique Mutualiste de l'Estuaire Cité Sanitaire Saint Nazaire, Centre Jean Perrin Clermont-Ferrand (UNICANCER/CJP), Centre Hospitalier Princesse Grace, FHU OncoAge - Pathologies liées à l’âge CHU Nice (OncoAge), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UniCA), Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital Lausanne (CHUV), Institut Bergonié Bordeaux, Respiratory Pathology Department, Centre Hospitalier de la Dracénie Draguignan, Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UniCA), Laboratoire International Associé Réponse des Organismes et Populations face au Stress Environnemental - Université Côte d’Azur - Centre Scientifique de Monaco (LIA ROPSE), Université Côte d’Azur - Centre Scientifique de Monaco, Centre Scientifique de Monaco (CSM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Micro-Environnement et Régulation Cellulaire Intégrée (MERCI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Avignon Université (AU), Institut des Biomolécules Max Mousseron Pôle Chimie Balard (IBMM), Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Université de Montpellier (UM), CRLCC René Gauducheau, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 (CHIMERE), Université de Picardie Jules Verne (UPJV)

Source: The lancet. Healthy longevity, vol. 5, no. 6, pp. e392-e405

Subject Terms: Male, Aged, 80 and over, Squamous Cell Carcinoma of Head and Neck, Cetuximab, [SDV.CAN]Life Sciences [q-bio]/Cancer, Humans, Aged, Female, Squamous Cell Carcinoma of Head and Neck/drug therapy, Squamous Cell Carcinoma of Head and Neck/pathology, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/pathology, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Fluorouracil/administration & dosage, Fluorouracil/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, Carboplatin/therapeutic use, Carboplatin/adverse effects, Cetuximab/administration & dosage, Cetuximab/therapeutic use, Cetuximab/adverse effects, Carboplatin, 3. Good health, [SDV.CAN] Life Sciences [q-bio]/Cancer, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Neoplasm Recurrence, Local

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38759667
https://u-picardie.hal.science/hal-04578230v1
https://doi.org/10.1016/s2666-7568(24)00048-5
https://u-picardie.hal.science/hal-04578230v1/document
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_FC7E3ACA49E02
https://serval.unil.ch/notice/serval:BIB_FC7E3ACA49E0
https://serval.unil.ch/resource/serval:BIB_FC7E3ACA49E0.P001/REF.pdf

Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study: A Danish national cohort study

Authors: Julie Haugaard Vandtved, Andreas Kiesbye Øvlisen, Joachim Baech, Ulla Møller Weinrich, Marianne Tang Severinsen, Eva Futtrup Maksten, Lasse Hjort Jakobsen, Ingrid Glimelius, Peter Kamper, Martin Hutchings, Lena Specht, Rasmus Dahl‐Sørensen, Jacob Haaber Christensen, Tarec C. El‐Galaly

Source: Vandtved, J H, Øvlisen, A K, Baech, J, Weinrich, U M, Severinsen, M T, Maksten, E F, Jakobsen, L H, Glimelius, I, Kamper, P, Hutchings, M, Specht, L, Dahl-Sørensen, R, Christensen, J H & El-Galaly, T C 2024, 'Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study', British Journal of Haematology, vol. 205, no. 2, pp. 542-551. https://doi.org/10.1111/bjh.19475
Vandtved, J H, Øvlisen, A K, Baech, J, Weinrich, U M, Severinsen, M T, Maksten, E F, Jakobsen, L H, Glimelius, I, Kamper, P, Hutchings, M, Specht, L, Dahl-Sørensen, R, Christensen, J H & El-Galaly, T C 2024, 'Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population : A Danish national cohort study', British Journal of Haematology, vol. 205, no. 2, pp. 542-551. https://doi.org/10.1111/bjh.19475

Subject Terms: Male, Adult, Lung Diseases, hodgkin lymphoma, Vincristine/adverse effects, Adolescent, Respiratory Medicine and Allergy, Denmark, Cyclophosphamide/adverse effects, Cohort Studies, Bleomycin/adverse effects, Bleomycin, Young Adult, Antineoplastic Combined Chemotherapy Protocols, late effects, Humans, obstructive lung diseases, Procarbazine/adverse effects, Cyclophosphamide, Lungmedicin och allergi, Aged, 2. Zero hunger, Cancer och onkologi, bleomycin, pulmonary fibrosis, Clinical Laboratory Medicine, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Incidence, Middle Aged, Hodgkin Disease, Denmark/epidemiology, 3. Good health, Hodgkin Disease/epidemiology, Klinisk laboratoriemedicin, Lung Diseases/chemically induced, Vincristine, Doxorubicin, Cancer and Oncology, Procarbazine, Female, pulmonary diseases, Doxorubicin/adverse effects

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38685596
https://vbn.aau.dk/ws/files/741350044/Vandtved_et_al._2024_._Pulmonary_diseases_in_patients_with_classical_Hodgkin_lymphoma_relative_to_a_matched_background_population_-_A_Danish_national_cohort_study.pdf
https://doi.org/10.1111/bjh.19475
https://vbn.aau.dk/da/publications/7152f7a6-e274-4d0f-84e6-03aab7e7348a
http://www.scopus.com/inward/record.url?scp=85191811569&partnerID=8YFLogxK
https://portal.findresearcher.sdu.dk/da/publications/6f09b6bc-ccf6-4b8b-bd5b-9fec6d58e515
https://doi.org/10.1111/bjh.19475
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-543565
https://pure.au.dk/portal/en/publications/cfb6e5b2-14dd-4b53-93f5-6cd31e3b017b
https://doi.org/10.1111/bjh.19475
http://www.scopus.com/inward/record.url?scp=85191811569&partnerID=8YFLogxK

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

Authors: Kim, Stefano, Ghiringhelli, Francois, de la Fouchardière, Christelle, Evesque, Ludovic, Smith, Denis, Badet, Nicolas, Samalin, Emmanuelle, Lopez-Trabada Ataz, Daniel, Parzy, Aurelie, Desramé, Jérôme, Baba Hamed, Nabil, Buecher, Bruno, Tougeron, David, Bouché, Olivier, Dahan, Laetitia, Chibaudel, Benoist, El Hajbi, Farid, Mineur, Laurent, Dubreuil, Olivier, Ben Abdelghani, Meher, Pecout, Solange, Bibeau, Frederic, Herfs, Michael, Garcia, Marie-Line, Meurisse, Aurelia, Vernerey, Dewi, Taïeb, Julien, Borg, Christophe

Contributors: Roche

Source: The Lancet Oncology. 25:518-528

Subject Terms: atezolizumab, Male, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Oncologie, Docetaxel, Fluorouracil/adverse effects, Middle Aged, Anus Neoplasms, Antibodies, Monoclonal, Humanized, Anus Neoplasms/drug therapy, Sciences de la santé humaine, B7-H1 Antigen, Neoplasm Recurrence, Local/drug therapy, Oncology, Cisplatin/adverse effects, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Humans, Female, Fluorouracil, Human health sciences, Cisplatin, Neoplasm Recurrence, Local, Aged

Access URL: https://pubmed.ncbi.nlm.nih.gov/38547895
https://hdl.handle.net/2268/316241
https://doi.org/10.1016/S1470-2045(24)00081-0

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

Authors: Nigel H. Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dillon, Steven Knapper, Leona M. Batten, Joanna Canham, Emily L. Hinson, Sophie Betteridge, Ulrik Malthe Overgaard, Amanda Gilkes, Nicola Potter, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D. Freeman, Mike Dennis, Maria Kallenbach, Marianne Severinsen, Mette Holm, Jan Maxwell Norgaard, Hans Beier Ommen, Dominic Culligan, Jane Tighe, Jenny Craig, Charles Crawley, Pramila Krishnamurthy, Walid Sadik, Jeffery Smith, Ranjit Dasgupta, Leanne Berkhan, Peter Bowett, Richard Doocey, Shannon Emmett, Timothy Hawkins, Nigel Patton, Lucy Pemberton, Alison Milne, Ashok Roy, Sylwia Simpson, Robert Cuthbert, Damian Finnegan, Mary Francis McMullin, Victoria Pechey, Richard Lovell, Donald Milligan, Shankara Paneesha, Paul Cahalin, P. Kelsey, Sam Ackroyd, Adrian Wiliams, Roger Evely, David Marks, Andrew Fletcher, Maryam Al-Ani, Khalil Ahmed, Richard Lush, Adam Rye, Robert Cutting, Emma Welch, Mark Wodzinski, Andrew Butler, Liam Fernyhough, Peter Ganly, Steve Gibbons, Mark Smith, Ruth Spearing, Andy Peniket, Faye Hatcliffe, Amit Patel, Kathrine Lindsay, Gillian Brearton, Salah Tuegar, S. Gandhi Anna Cowley, Adrian Copplestone, Hannah Hunter, Patrick Medd, Tim Nokes, Simon Rule, Wayne Thomas, Joe Joseph, Stuti Kaul, Youssef Sorour, Shingi Chvuka, Hilda Mangos, Annette Neylon, Katrina Farrell, Hugh Edwards, Katharine Hanlon, Tom Fail, Margaret Goodrick, Earnest Heartin, Christine Hoyle, Robert Carr, Kavita Raj, Morten Krogh Jensen, Riaz Janmohamed, Richard Kaczmarski, Taku Sugai, Debo Ademokun, Isobel Chalmers, Andrew Hodson, Cesar Gomez, Shala Sadullah, Mark Kwan, Karyn Longmuir, Isaac Wilson-Morkeh, Ann Hunter, Murray Martin, Kandeepan Saravanamuttu, Gamal Sidra, Sarah Burns, Simon Gibbs, Eleni Tholouli, Maadh Aldouri, Vivienne Andrews, Ayed Eden, Moez Dungarwalla, Denise White, Jane Laird, Lindsey Mitchell, John Murphy, Pamela Paterson, Alaeddin Raafat, Deepak Mannari, Simon Davies, Belinda Austen, Sarah Allford, Sudhakar Kakalamudi, Supratik Basu, Sunil Hada, Abraham Jacob, Alan MacWhonell, Alison McCaig, Keith Gelly, Ron Kerr, David Meiklejohn, Sudhir Tauro, Matthew Lawes, Angela Bowen, Suchitra Krishnamurthy, Jenny Byrne, Emma Dasgupta, Nigel Russell, Simone Stokley, Lone Friis, Claus Marcher, Bart Bake, Mary Chapple, Paul Moreton, Asad Omran, Kavita Patil, David Wright, Fergus Jack, Rebecca Maddams, Robert Corser, Tanya Cranfield, Helen Dignum, Mary Ganczakowski, Christopher Jones, Charles Craddock, Paula Moss, Jim Murray, Joanne Craig, Peter Forsyth, Chris Lush, Ole Wei Bjerrum, Niels Borregaard, Peter Kampmann, Lars Kjeldsen, Ove Juul Nielsen, Carsten Niemann, Soeren Lykke Petersen, Lene Udby Peter Møller, Arun Alfred, Helen Barker, Richard Went, Henri Groch, Stuart Mucklow, Rebecca Sampson, Joseph Chacko, Rachel Hall, Renata Walewska, Desmond Creach, Bryson Pottinger, Juanah (Jo) Addada, Malcolm Hamilton, Paul Kerr, Loretta Ngu, Claudius Rudin, Jackie Ruell, Chris Dalley, Harpreet Kaur, John Reilly, John Snowden, Paul Ferguson, Peter Dyer, Deepak Chandra, Johannes DeVos, Elisabeth Grey-Davies, Louise Hendry, Timothy Corbett, Josephine Crowe, Christopher Knechtli, Sarah Wexler, Savio Fernandes, Jeff Neilson, John Houghton, Simon Jowitt, Rowena Thomas-Dewing, Mark Williams, Sonya Zaman, Jonathan Cullis, Tamara Everington, Effie Grand, Yasmin Hasan, Richard Murrin, Farooq Wandoo, Saad Ismail, Unmesh Mohite, Hamdi Sati, Matthew Jenner, Kim Orchard, Deborah Richardson, Kayleigh McCloskey, Kate Xu Chin, Neoh Fenella Willis, Amit Sud, Maged Gharib, Toby Nicholson, David Bowen, Sarah Janes, Helen Eagleton, Anne-Marie O'Hea, Jonathan Pattinson, Victoria Hervey, Simon Lyons, Scott Marshall, Annette Nicolle, Maria Vavyla, Jordan Burgess, Tim Somervaille, Sven Somerfield, Mohd Mamat, Jo Tomlins, Sana Salesh, Marianna David, Jamie Maddox, Diane Plews, Ray Dang, Mike Potter, Lauren Ellis, Emma Nicholson, Sally Keat, Thubeena M. Ahmed Alhassani, Farahn Anjum, Poulami Chatterjee, Atanas Stanchev, Jayne Peters, Sarah Lindsay-Holmes Srividhya, Senthil S. Chodhouri, Heather Eve, Steve Smith, Patrick Roberts, Nicholas Rymes, Rui Zhao New Oo, Kirit Ardeshna, Piers Blombery, Asim Khwaja, David Linch, Rakesh Popat, Andres Virchis, Kwee Yong, Victoria McIntyre, Gillian Horne, Syed Bokhari, Anton Borg, Oliver Chapman, Beth Harrison, Nicholas Jackson, Shailesh Jobanputra, Mekkali Narayanan, Peter Rose, Hajer Oun, Matthew Powell, Julie Gilles, Alison Laing, Ian Devanny, Lea Haskins, Paul Micallef-Eynaud, Peter Maclean, Caroline Alvares, Jonathan Kell, Steve Knapper, Kerri Davidson, Lorna McLintock, Stephen Rogers, Peter Williamson, Gillian Corbett, Hugh Goodman, Shahid Islam, Humphrey Pullon, Peter Johnson, P.H. Roddie, Elizabeth Maughan, Juliet Mills, Salim Shafeek, Santosh Narat, Robin Aitchison, Lee Bond, Laura Munro, David Edwards

Source: J Clin Oncol
Russell, N H, Wilhelm-Benartzi, C, Othman, J, Dillon, R, Knapper, S, Batten, L M, Canham, J, Hinson, E L, Betteridge, S, Overgaard, U M, Gilkes, A, Potter, N, Mehta, P, Kottaridis, P, Cavenagh, J, Hemmaway, C, Arnold, C, Freeman, S D, Dennis, M, UK NCRI AML Working Group & Severinsen, M 2024, 'Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations', Journal of Clinical Oncology, vol. 42, no. 10, pp. 1158-1168. https://doi.org/10.1200/JCO.23.00943
Russell, N H, Wilhelm-Benartzi, C, Othman, J, Dillon, R, Knapper, S, Batten, L M, Canham, J, Hinson, E L, Betteridge, S, Overgaard, U M, Gilkes, A, Potter, N, Mehta, P, Kottaridis, P, Cavenagh, J, Hemmaway, C, Arnold, C, Freeman, S D, Dennis, M & UK NCRI AML Working Group 2024, 'Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations', Journal of Clinical Oncology, vol. 42, no. 10, pp. 1158-1168. https://doi.org/10.1200/JCO.23.00943

Subject Terms: Myeloid, Adult, Leukemia, Myeloid, Acute/drug therapy, Cytarabine/therapeutic use, Local/drug therapy, Granulocyte Colony-Stimulating Factor/therapeutic use, Recurrence, Granulocyte Colony-Stimulating Factor, Antineoplastic Combined Chemotherapy Protocols, Acute/drug therapy, Humans, Leukemia, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Core Binding Factors, Cytarabine, Nuclear Proteins, ORIGINAL REPORTS, Gemtuzumab/therapeutic use, Gemtuzumab, Progression-Free Survival, 3. Good health, Nuclear Proteins/genetics, Leukemia, Myeloid, Acute, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, fms-Like Tyrosine Kinase 3, Vidarabine/therapeutic use, Mutation, Neoplasm Recurrence, Local, Idarubicin, Vidarabine

Access URL: https://pubmed.ncbi.nlm.nih.gov/38215358
https://vbn.aau.dk/da/publications/990f6b6f-0469-4c04-8e6c-e4729c7fcdce
http://www.scopus.com/inward/record.url?scp=85188441493&partnerID=8YFLogxK
https://doi.org/10.1200/JCO.23.00943
https://portal.findresearcher.sdu.dk/da/publications/e52f8edc-912e-491d-9f70-e15094721b28
https://doi.org/10.1200/JCO.23.00943
http://www.scopus.com/inward/record.url?scp=85188441493&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/706f709d-396d-48d1-8214-6c91f7effa6f
https://doi.org/10.1200/JCO.23.00943

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Authors: Lucas Moreno, Rebekah Weston, Cormac Owens, Dominique Valteau-Couanet, Marion Gambart, Victoria Castel, C. Michel Zwaan, Karsten Nysom, Nicolas Gerber, Aurora Castellano, Genevieve Laureys, Ruth Ladenstein, Jochen Rössler, Guy Makin, Dermot Murphy, Bruce Morland, Sucheta Vaidya, Estelle Thebaud, Natasha van Eijkelenburg, Deborah A. Tweddle, Giuseppe Barone, Julie Tandonnet, Nadege Corradini, Pascal Chastagner, Catherine Paillard, Francisco J. Bautista, Soledad Gallego Melcon, Bram De Wilde, Lynley Marshall, Juliet Gray, Susan A. Burchill, Gudrun Schleiermacher, Louis Chesler, Andrew Peet, Martin O. Leach, Kieran McHugh, Roisin Hayes, Neil Jerome, Hubert Caron, Jennifer Laidler, Nicola Fenwick, Grace Holt, Veronica Moroz, Pamela Kearns, Simon Gates, Andrew D.J. Pearson, Keith Wheatley, Francisco José Bautista, Estelle Thebaut, Dave Hobin, Martin Elliott, Deborah Tweddle, Sarah Jannier, Soledad Gallego, Carole Coze, Anne Auvrignon, Anne Sophie Defachelles, Ricardo Lopez Almaraz, Benedicte Brichard, Roberto Luksch, Michel Zwaan, Beck Popovic Maja, Courtney Willis, Simone Hettmer, Lothar Schweigerer, Udo Kontny, Holger Christiansen, Alberto Garaventa, Anthony Ng, Lisa Howell, Daniel Yeomanson

Contributors: Institut Català de la Salut, [Moreno L] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Weston R] University of Birmingham, Birmingham, United Kingdom. [Owens C] Children’s Hospital Ireland, Dublin, Ireland. [Valteau-Couanet D] Institut Gustave Roussy, Paris, France. [Gambart M] Hôpital des Enfants, Bordeaux, France. [Castel V] Hospital Universitario La Fe, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, UCL - SSH/IACS - Institute of Analysis of Change in Contemporary and Historical Societies

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Instituto de Investigación Sanitaria La Fe (IIS La Fe)
Journal of clinical oncology, Vol. 42, no.10, p. 1135-1145 (2024)
Journal of Clinical Oncology, Vol. 42, no. 10, p. 1135-1145 (2024)
Moreno, Lucas; Weston, Rebekah; Owens, Cormac; Valteau-Couanet, Dominique; Gambart, Marion; Castel, Victoria; Zwaan, C Michel; Nysom, Karsten; Gerber, Nicolas; Castellano, Aurora; Laureys, Genevieve; Ladenstein, Ruth; Rössler, Jochen; Makin, Guy; Murphy, Dermot; Morland, Bruce; Vaidya, Sucheta; Thebaud, Estelle; van Eijkelenburg, Natasha; Tweddle, Deborah A; ... (2024). Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(10), pp. 1135-1145. American Society of Clinical Oncology 10.1200/JCO.23.00458 <http://dx.doi.org/10.1200/JCO.23.00458>
Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN) 2024, 'Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma : Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 42, no. 10, pp. 1135-1145. https://doi.org/10.1200/JCO.23.00458

Subject Terms: Adult, Irinotecan/therapeutic use, Adolescent, Neuroblastoma/pathology, Neuroblastoma - Tractament, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Otros calificadores::Otros calificadores::/uso terapéutico, 610 Medicine & health, Bevacizumab/adverse effects, Irinotecan, Quimioteràpia combinada, Local/drug therapy, Young Adult, Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols, Temozolomide, Humans, Preschool, Child, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Temozolomide/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma, Infant, ORIGINAL REPORTS, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::Neuroblastoma, 3. Good health, Bevacizumab, Dacarbazine, Neoplasm Recurrence, Local/drug therapy, n/a, Neoplasm Recurrence, Dacarbazine/adverse effects, Child, Preschool, Neoplasm Recurrence, Local, Topotecan, Topotecan/adverse effects

File Description: application/pdf; text

Access URL: https://pubmed.ncbi.nlm.nih.gov/38190578
https://hdl.handle.net/11351/11285
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=23110
https://research.manchester.ac.uk/en/publications/944d5674-73a6-4896-aa91-1f66999478f5
https://doi.org/10.1200/JCO.23.00458
https://hdl.handle.net/2078.1/301498
https://hdl.handle.net/2078.1/298291
https://boris.unibe.ch/191348/
https://eprints.soton.ac.uk/485710/

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Authors: Balmaña, Judith, Fasching, Peter A., Couch, Fergus, Delaloge, Suzette, labidi-galy, sana intidhar, O’Shaughnessy, Joyce, Park, Yeon Hee, Eisen, Andrea, You, Benoit, Bourgeois, Hughes, Gonçalves, Anthony, Kemp, Zoe, Swampillai, Angela, Jankowski, Tomasz, Sohn, Joohyuk, Poddubskaya, Elena, Mukhametshina, Guzel, AKSOY, SERCAN, Timcheva, Constanta, Park-Simon, Tjoung-Won, Antón Torres, Antonio, John, Ellie, Baria, Katherine, Gibson, Isabel, Gelmon, Karen, The LUCY investigators, Bulgaria, Koynova, Tatyana, Popov, Vasil, Tomova, Antoaneta, Canada, Lemieux, Julie, France, Augereau, Paule, Bazan, Fernando, Becuwe, Célia, Bourgeois, Hugues, Chakiba, Camille, Chehimi, Mohamad, Cheneau, Caroline, Dalenc, Florence, de Guillebon, Eléonore, de La Motte Rouge, Thibault, Frenel, Jean-Sébastien, Grenier, Julien, Hardy-Bessard, Anne Claire, Lamy, Regine, Levy, Christelle, Lortholary, Alain, Mailliez, Audrey, Medioni, Jacques, Patsouris, Anne, Spaeth, Dominique, Teixeira, Luis, Tennevet, Isabelle, Venat-Bouvet, Laurence, Villanueva, Cristian, Germany, Ettl, Johannes, Fasching, Peter, Gerber, Bernd, Hanusch, Claus Alexander, Hoffmann, Oliver, Malter, Wolfram, Reinisch, Mattea, Tio, Joke, Wimberger, Pauline, Hungary, Boer, Katalin, Dank, Magdolna, Italy, Ballestrero, Alberto, Bianchini, Giampaolo, Biganzoli, Laura, Bordonaro, Roberto, Cognetti, Francesco, Cortesi, Enrico, De Laurentiis, Michelino, De Placido, Sabino, Gianni, Luca, Guarneri, Valentina, Marchetti, Paulo, Montemurro, Filippo, Mosconi, Anna Maria, Naso, Giuseppe, Puglisi, Fabio, Santoro, Armando, Zamagni, Claudio, Japan, Iwata, Hiroji, Kim, Seung-Jin, Nakamura, Seigo, Korea, Chae, Yee Soo, Cho, Eun Kyung, Kim, Jee Hyun, Im, Seock-Ah, Lee, Keun Seok, Sohn, Joo Hyuk, Poland, Byrski, Tomasz, Huzarski, Tomasz, Kukielka-Budny, Bozena, Lacko, Aleksandra, Nowecki, Zbigniew, Senkus-Konefka, Elzbieta, Szoszkiewicz, Renata, Tarnawski, Rafal, Russia, Andabekov, Timur, Dvorkin, Mikhail, Dvornichenko, Viktoria, Moiseenko, Fedor, Popova, Ekaterina, Tarasova, Anna, Sakaeva, Dina, Shomova, Marina, Vats, Anna, Spain, Adamo, Bárbara, Conejero, Raquel Andrés, Torres, Antonio Antón, Gelpi, Judith Balmaña, de Ibarguen, Blanca Cantos Sánchez, Jurado, Josefina Cruz, Fernández, Nieves Díaz, González, Alejandro Falcón, Garcia, Juan, Santiago, Santiago González, Carrasco, Fernando Henao, Lorenzo, Isabel Lorenzo, Antón, Fernando Moreno, García, Beatriz Rojas, Beltrán, Salomón Menjón, Santisteban, Marta, Stradella, Agostina, Taiwan, Hou, Ming-Feng, Huang, Chiun-Sheng, Lin, Yung-Chang, Tseng, Ling-Ming, Wang, Hwei-Chung, Turkey, Aksoy, Sercan, Arslan, Cagatay, Artac, Mehmet, Aydiner, Adnan, Disel, Umut, Ozkan, Metin, Ozyilkan, Ozgur, Sezer, Emel Yaman, Yetisyigit, Tarkan, Armstrong, Anne, Barrett, Sophie, Borley, Annabel, Michie, Caroline, Mukesh, Mukesh, Perren, Timothy, USA, Chaudhry, Madhu, Young, Tammy

Contributors: Institut Català de la Salut, [Balmaña J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fasching PA] Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. [Couch FJ] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. [Delaloge S] Breast Cancer Unit, Department of Cancer Medicine, Gustave Roussy, Villejuif, France. [Labidi Galy I] Department of Oncology, Geneva University Hospital, Department of Medicine, Division of Oncology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. [O’Shaughnessy J] Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA, Vall d'Hebron Barcelona Hospital Campus

Source: Breast Cancer Res Treat
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, 0301 basic medicine, Breast Neoplasms / drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Breast cancer, Breast cancer 1 gene product, Breast cancer 2 gene product, Kaplan–Meier survival curves, Olaparib, Overall survival, Progression-free survival, Medicaments antineoplàstics - Ús terapèutic, Breast Neoplasms, Piperazines, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Humans, Germ-Line Mutation, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Clinical Trial, 3. Good health, Female [MeSH], Adult [MeSH], Humans [MeSH], Breast Neoplasms/genetics [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Piperazines [MeSH], Germ-Line Mutation [MeSH], Phthalazines/adverse effects [MeSH], Breast Neoplasms / genetics, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Treatment Outcome, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), Phthalazines, Female, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Phthalazines / adverse effects, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38112922
https://hdl.handle.net/11351/11260
https://hdl.handle.net/11588/963536
https://link.springer.com/article/10.1007/s10549-023-07165-x
https://doi.org/10.1007/s10549-023-07165-x
https://archive-ouverte.unige.ch/unige:179164
https://doi.org/10.1007/s10549-023-07165-x
https://repository.publisso.de/resource/frl:6501358
https://hdl.handle.net/11588/963536
https://doi.org/10.1007/s10549-023-07165-x

10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial: an open-label, randomised, controlled, phase 3 trial

Authors: Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, Huls, Gerwin, Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W. M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, de Jonge-Peeters, Susan Dorothé

Contributors: KWF - Kankerbestrijding, DJCLS - José Carreras Leukämie-Stiftung, Janssen Pharmaceuticals, DFG - Deutsche Forschungsgemeinschaft, Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimona, Neubauer, Andrea, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mel, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, Huls, Gerwin, Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andriu, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W. M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, de Jonge-Peeters, Susan Dorothé, Lübbert, M, Wijermans, Pw, Kicinski, M, Chantepie, S, Van der Velden, Wjfm, Noppeney, R, Griškevičius, L, Neubauer, A, Crysandt, M, Vrhovac, R, Luppi, M, Fuhrmann, S, Audisio, E, Candoni, A, Legrand, O, Foà, R, Gaidano, G, van Lammeren-Venema, D, Posthuma, Efm, Hoogendoorn, M, Giraut, A, Stevens-Kroef, M, Jansen, Jh, de Graaf, Ao, Efficace, F, Ammatuna, E, Vilque, J, Wäsch, R, Becker, H, Blijlevens, N, Dührsen, U, Baron, F, Suciu, S, Amadori, S, Venditti, A, Huls, G

Source: Lancet Haematology, 10, 11, pp. E879-E889

Subject Terms: Daunorubicin/therapeutic use, Cytarabine / therapeutic use, Decitabine/therapeutic use, Medizin, Leukemia, Myeloid, Acute/drug therapy, Radboud University Medical Center, Daunorubicin / therapeutic use, Radboudumc 2: Cancer development and immune defence Laboratory Medicine, Cytarabine/therapeutic use, Decitabine, Sciences de la santé humaine, AML, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Radboudumc 9: Rare cancers Haematology, Leukemia, Myeloid, Acute / diagnosis, Humans, Transplantation, Homologous, decitabine, allografting, acute myeloid leukaemia, Human health sciences, Aged, intensive chemotherapy, Radboudumc 2: Cancer development and immune defence Human Genetics, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Daunorubicin, Cytarabine, AML, decitabine, intensive chemotherapy, HSCT, Hematology, Middle Aged, Settore MED/15, Leukemia, Myeloid, Acute/diagnosis, 3. Good health, Leukemia, Myeloid, Acute, Decitabine / therapeutic use, Radboudumc 5: Inflammatory diseases Haematology, HSCT, Leukemia, Myeloid, Acute / drug therapy, decitabine, Hématologie

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37914482
https://research.rug.nl/en/publications/41ef0758-ce49-4743-abbd-f82d1337df47
https://doi.org/10.1016/S2352-3026(23)00273-9
https://hdl.handle.net/11370/41ef0758-ce49-4743-abbd-f82d1337df47
https://repository.ubn.ru.nl//bitstream/handle/2066/301144/301144.pdf
https://hdl.handle.net/2066/301144
https://urn.nsk.hr/urn:nbn:hr:105:992101
https://doi.org/10.1016/s2352-3026(23)00273-9

The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study: the NOVIT study

Authors: Eva Futtrup Maksten, Carsten Dahl Mørch, Lasse Hjort Jakobsen, Kristian Hay Kragholm, Pernille From Blindum, Mikkel Runason Simonsen, Niels Ejskjaer, Karen Dybkær, Henrik Gregersen, Jakob Madsen, Tarec C. El-Galaly, Marianne Tang Severinsen

Source: Support Care Cancer
Maksten, E F, Mørch, C D, Jakobsen, L H, Kragholm, K H, Blindum, P F, Simonsen, M R, Ejskjaer, N, Dybkær, K, Gregersen, H, Madsen, J, El-Galaly, T C & Severinsen, M T 2025, 'The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study', Supportive Care in Cancer, vol. 33, no. 3, 225. https://doi.org/10.1007/s00520-025-09282-3

Subject Terms: Male, Adult, Numbness, Vincristine/adverse effects, Lymphoma, Peripheral Nervous System Diseases/chemically induced, Antineoplastic Agents, Survivorship, Hematologic Neoplasms/drug therapy, Bortezomib, Multiple myeloma, Antineoplastic Combined Chemotherapy Protocols, Lenalidomide/administration & dosage, Tingling, Humans, Longitudinal Studies, Lenalidomide, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Research, Peripheral Nervous System Diseases, Antineoplastic Agents/adverse effects, Middle Aged, Vincristine, Hematologic Neoplasms, Female, Bortezomib/adverse effects

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40011273
http://www.scopus.com/inward/record.url?scp=85218734211&partnerID=8YFLogxK
https://vbn.aau.dk/ws/files/768536239/s00520-025-09282-3.pdf
https://vbn.aau.dk/da/publications/cb37d27b-cd7e-47c8-8b45-e914f34be36e
https://doi.org/10.1007/s00520-025-09282-3
https://portal.findresearcher.sdu.dk/da/publications/bedcb2f2-adb6-4de8-a18b-badf1f136e60
https://doi.org/10.1007/s00520-025-09282-3